WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1994027593) USE OF 12-DEOXYPHORBOL 13-MONOESTERS FOR INHIBITING NEOPLASIA AND TUMOR PROMOTION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1994/027593    International Application No.:    PCT/US1994/005630
Publication Date: 08.12.1994 International Filing Date: 19.05.1994
Chapter 2 Demand Filed:    15.12.1994    
IPC:
A61K 31/215 (2006.01), A61K 31/22 (2006.01), A61K 31/235 (2006.01)
Applicants: THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, Box OTT, Bethesda, MD 20892-9902 (US)
Inventors: BLUMBERG, Peter, M.; (US).
SZALLASI, Zoltan; (US)
Agent: KILYK, John, Jr.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US)
Priority Data:
064,251 20.05.1993 US
Title (EN) USE OF 12-DEOXYPHORBOL 13-MONOESTERS FOR INHIBITING NEOPLASIA AND TUMOR PROMOTION
(FR) UTILISATION DE 13-MONOESTERS DE 12-DESOXYPHORBOL POUR INHIBER LA NEOPLASIE ET L'ACTIVATION TUMORALE
Abstract: front page image
(EN)The present invention provides a method of inhibiting neoplasia and tumor promotion. The method comprises administering to a mammal, particularly a human, in need thereof an effective amount of a 12-deoxyphorbol ester, particularly a 12-deoxyphorbol 13-monoester such as 12-deoxyphorbol 13-acetate (prostratin) and 12-deoxyphorbol 13-phenylacetate (dPP).
(FR)L'invention concerne un procédé d'inhibition de la néoplasie et de l'activation tumorale. Ledit procédé consiste à administrer à un mammifère, particulièrement à un humain à traiter, une dose efficace d'ester de 12-désoxyphorbol, plus spécifiquement un 13-monoester de 12-désoxyphorbol tel que du 13-acétate de 12-désoxyphorbol (prostatine) et du 13-phénylacétate de 12-désoxyphorbol (dPP).
Designated States: AU, CA, JP.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)